[
  {
    "ts": null,
    "headline": "Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports",
    "summary": "The drug maker's acquisition bid includes a payment of almost $1 billion upfront for Verve, and a further $300 million based on the genetic medicines company achieving certain clinical milestones, the report said, citing people familiar with the matter.  Verve Therapeutics is currently developing a gene therapy to reduce high cholesterol levels, which is expected to be used in combination with other drugs.  Eli Lilly declined to comment, while Verve Therapeutics did not immediately respond to a Reuters request for comment outside regular business hours.",
    "url": "https://finnhub.io/api/news?id=0ec17d483c797743dfcd884a96802b5c5e5151e6563c0334f445d3f314d0ed09",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750117742,
      "headline": "Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports",
      "id": 135312467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drug maker's acquisition bid includes a payment of almost $1 billion upfront for Verve, and a further $300 million based on the genetic medicines company achieving certain clinical milestones, the report said, citing people familiar with the matter.  Verve Therapeutics is currently developing a gene therapy to reduce high cholesterol levels, which is expected to be used in combination with other drugs.  Eli Lilly declined to comment, while Verve Therapeutics did not immediately respond to a Reuters request for comment outside regular business hours.",
      "url": "https://finnhub.io/api/news?id=0ec17d483c797743dfcd884a96802b5c5e5151e6563c0334f445d3f314d0ed09"
    }
  },
  {
    "ts": null,
    "headline": "Why Novo Nordisk Stock Sank by Nearly 4% Today",
    "summary": "On top of that, an analyst cut his price target on the Denmark-based pharmaceutical company.  Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish pharmaceutical company.  A price target cut from an analyst tracking the company only exacerbated the situation.",
    "url": "https://finnhub.io/api/news?id=224b3bbd0e3886b0372e59e91800b16b5831cbd92f85a83adda589d0bc318ba8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750112488,
      "headline": "Why Novo Nordisk Stock Sank by Nearly 4% Today",
      "id": 135311663,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On top of that, an analyst cut his price target on the Denmark-based pharmaceutical company.  Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish pharmaceutical company.  A price target cut from an analyst tracking the company only exacerbated the situation.",
      "url": "https://finnhub.io/api/news?id=224b3bbd0e3886b0372e59e91800b16b5831cbd92f85a83adda589d0bc318ba8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts",
    "summary": "In the closing of the recent trading day, Eli Lilly (LLY) stood at $807.58, denoting a -1.44% move from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=929d97a6ffd380a3efa04f61eeb0ec686d96fb45dc377a7f87043d279505d742",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750110302,
      "headline": "Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts",
      "id": 135313679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Eli Lilly (LLY) stood at $807.58, denoting a -1.44% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=929d97a6ffd380a3efa04f61eeb0ec686d96fb45dc377a7f87043d279505d742"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q1 2025 Update",
    "summary": "AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a quantitative, diversified approach. See more.",
    "url": "https://finnhub.io/api/news?id=51b45bd42e92498ec52abd010edf461044394127b04a8428f9c402a3b43b4ef8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750108183,
      "headline": "Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q1 2025 Update",
      "id": 135312158,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a quantitative, diversified approach. See more.",
      "url": "https://finnhub.io/api/news?id=51b45bd42e92498ec52abd010edf461044394127b04a8428f9c402a3b43b4ef8"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push",
    "summary": "June 17 - Eli Lilly will acquire gene-editing startup VerveTherapeutics for up to $1.3 billion, the companies saidon Tuesday, to boost its pipeline of experimental medicinesbeyond...",
    "url": "https://finnhub.io/api/news?id=88b6ce3f321c5422ada070912f6a86eb3b42806178899ce17c644ecc82f3fd26",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750104613,
      "headline": "Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push",
      "id": 135325785,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "June 17 - Eli Lilly will acquire gene-editing startup VerveTherapeutics for up to $1.3 billion, the companies saidon Tuesday, to boost its pipeline of experimental medicinesbeyond...",
      "url": "https://finnhub.io/api/news?id=88b6ce3f321c5422ada070912f6a86eb3b42806178899ce17c644ecc82f3fd26"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly strikes $1.3 billion deal to buy gene-editing biotech Verve Therapeutics, companies say",
    "summary": "June 17 - Eli Lilly will acquire gene-editing startup VerveTherapeutics for up to $1.3 billion, the companies saidon Tuesday, sending Verve's shares up 77.7% in premarkettrading. ...",
    "url": "https://finnhub.io/api/news?id=59b287154dc4009e8e1952ca3965975dfb53f54f1dc12ba6061531809b94fc54",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750104613,
      "headline": "Eli Lilly strikes $1.3 billion deal to buy gene-editing biotech Verve Therapeutics, companies say",
      "id": 135325344,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "June 17 - Eli Lilly will acquire gene-editing startup VerveTherapeutics for up to $1.3 billion, the companies saidon Tuesday, sending Verve's shares up 77.7% in premarkettrading. ...",
      "url": "https://finnhub.io/api/news?id=59b287154dc4009e8e1952ca3965975dfb53f54f1dc12ba6061531809b94fc54"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Close To Buying Gene-Editing Biotech Verve Therapeutics - FT",
    "summary": "June 16 - * ELI LILLY CLOSE TO BUYING GENE-EDITING BIOTECH VERVETHERAPEUTICS- FT * ELI LILLY IS IN ADVANCED TALKS TO BUY GENE EDITINGSTART-UPVERVE THERAPEUTICS FOR UP...",
    "url": "https://finnhub.io/api/news?id=29a5df08bfe68403ced0396ada8cb787d9acc1f02daf0baa4fe068370ae19ad7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750102568,
      "headline": "Eli Lilly Close To Buying Gene-Editing Biotech Verve Therapeutics - FT",
      "id": 135311574,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "June 16 - * ELI LILLY CLOSE TO BUYING GENE-EDITING BIOTECH VERVETHERAPEUTICS- FT * ELI LILLY IS IN ADVANCED TALKS TO BUY GENE EDITINGSTART-UPVERVE THERAPEUTICS FOR UP...",
      "url": "https://finnhub.io/api/news?id=29a5df08bfe68403ced0396ada8cb787d9acc1f02daf0baa4fe068370ae19ad7"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?",
    "summary": "NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.",
    "url": "https://finnhub.io/api/news?id=2fbb8e3b34420d6c2e84d4a4a09b05cece9f81009fa68637b33ae6a33b35ec49",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750091700,
      "headline": "Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?",
      "id": 135311664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.",
      "url": "https://finnhub.io/api/news?id=2fbb8e3b34420d6c2e84d4a4a09b05cece9f81009fa68637b33ae6a33b35ec49"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=9153f2c7f0b6ede0804cf3b9823e766a6ca941c41b7a37e6eafa5e6edb223eb1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750091460,
      "headline": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
      "id": 135329338,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=9153f2c7f0b6ede0804cf3b9823e766a6ca941c41b7a37e6eafa5e6edb223eb1"
    }
  },
  {
    "ts": null,
    "headline": "PFE or LLY: Which Is the Better Value Stock Right Now?",
    "summary": "PFE vs. LLY: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=d02ea02130a076be67252f2130b2af49278d156e83ac6668b6824732440626c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750088404,
      "headline": "PFE or LLY: Which Is the Better Value Stock Right Now?",
      "id": 135313683,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "PFE vs. LLY: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=d02ea02130a076be67252f2130b2af49278d156e83ac6668b6824732440626c3"
    }
  },
  {
    "ts": null,
    "headline": "BeOne Medicines: Brukinsa Momentum And Pipeline Catalysts Justify Its Premium",
    "summary": "Discover why BeOne Medicines (BEIGF) is a strong Buy with growth driven by Brukinsa, Tevimbra, and a promising oncology pipeline.",
    "url": "https://finnhub.io/api/news?id=48d2aa2b51419359ce3895ab9e676565b220c2273b8f4d8975dc223b1df171fe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750071968,
      "headline": "BeOne Medicines: Brukinsa Momentum And Pipeline Catalysts Justify Its Premium",
      "id": 135305491,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160714898/image_2160714898.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why BeOne Medicines (BEIGF) is a strong Buy with growth driven by Brukinsa, Tevimbra, and a promising oncology pipeline.",
      "url": "https://finnhub.io/api/news?id=48d2aa2b51419359ce3895ab9e676565b220c2273b8f4d8975dc223b1df171fe"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month through LillyDirect's Self Pay Pharmacy Solutions and the Zepbound Self Pay Journey Program.1 Health care providers can begin prescribing the 12.5 mg and 15 mg vials on July 7, and shipments to patients will begin in early August. With the addition of these doses, every strength of Zepbound vial will be availa",
    "url": "https://finnhub.io/api/news?id=281a88a5d794994dbac47adbdf9d95cff7c1ebc615d0e13c618df696376b7793",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750070700,
      "headline": "Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions",
      "id": 135302882,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month through LillyDirect's Self Pay Pharmacy Solutions and the Zepbound Self Pay Journey Program.1 Health care providers can begin prescribing the 12.5 mg and 15 mg vials on July 7, and shipments to patients will begin in early August. With the addition of these doses, every strength of Zepbound vial will be availa",
      "url": "https://finnhub.io/api/news?id=281a88a5d794994dbac47adbdf9d95cff7c1ebc615d0e13c618df696376b7793"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly CFO’s on-stage comment shows the high stakes of public speaking: Trial Balance",
    "summary": "As more CFOs step into the public spotlight by participating in events and conferences, the cost of misspeaking and the importance of leadership alignment on policy are increasing.",
    "url": "https://finnhub.io/api/news?id=1fa87f8c94e52df4e4b63aa67d92336cc6d262e4fa619712251ecabc746c2a4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750068000,
      "headline": "Eli Lilly CFO’s on-stage comment shows the high stakes of public speaking: Trial Balance",
      "id": 135309025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As more CFOs step into the public spotlight by participating in events and conferences, the cost of misspeaking and the importance of leadership alignment on policy are increasing.",
      "url": "https://finnhub.io/api/news?id=1fa87f8c94e52df4e4b63aa67d92336cc6d262e4fa619712251ecabc746c2a4c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: a single price to expand access to Zepbound",
    "summary": "Eli Lilly announced Monday that the highest doses of its flagship weight-loss treatment, Zepbound, will now be available in single-dose vials at a fixed monthly price of $499 through its...",
    "url": "https://finnhub.io/api/news?id=cccbcd92a8db69d27f85c00c2ccede546e44a128ad39da2cc6a979d56cf615e4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750062143,
      "headline": "Eli Lilly: a single price to expand access to Zepbound",
      "id": 135300195,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly announced Monday that the highest doses of its flagship weight-loss treatment, Zepbound, will now be available in single-dose vials at a fixed monthly price of $499 through its...",
      "url": "https://finnhub.io/api/news?id=cccbcd92a8db69d27f85c00c2ccede546e44a128ad39da2cc6a979d56cf615e4"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: An Elite Company That Prints Money",
    "summary": "We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.",
    "url": "https://finnhub.io/api/news?id=a948ec075ad3d682f393eeda65467f44b71341161490c17acdaf6c8013ac19f7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750060800,
      "headline": "Novo Nordisk: An Elite Company That Prints Money",
      "id": 135300056,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2112991930/image_2112991930.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock. ",
      "url": "https://finnhub.io/api/news?id=a948ec075ad3d682f393eeda65467f44b71341161490c17acdaf6c8013ac19f7"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to offer higher-dose versions of weight-loss drug on website",
    "summary": "U.S. drugmaker Eli Lillysaid on Monday it will offer the higher-dose versions of itspopular weight-loss drug Zepbound on its website LillyDirect,with shipments starting in early August. ...",
    "url": "https://finnhub.io/api/news?id=b9de7c1a81a1de74a281405381c10f680a5903abd3a20a0c0029efb59e122cdc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750058169,
      "headline": "Lilly to offer higher-dose versions of weight-loss drug on website",
      "id": 135299643,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "U.S. drugmaker Eli Lillysaid on Monday it will offer the higher-dose versions of itspopular weight-loss drug Zepbound on its website LillyDirect,with shipments starting in early August. ...",
      "url": "https://finnhub.io/api/news?id=b9de7c1a81a1de74a281405381c10f680a5903abd3a20a0c0029efb59e122cdc"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to offer highest doses of weight-loss drug Zepbound on website",
    "summary": "Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday. With...",
    "url": "https://finnhub.io/api/news?id=8ec7a59173bc26eaf68d8283efc61300894274ae6b5a7a983d7caf3019fcef0e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750057511,
      "headline": "Lilly to offer highest doses of weight-loss drug Zepbound on website",
      "id": 135300682,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday. With...",
      "url": "https://finnhub.io/api/news?id=8ec7a59173bc26eaf68d8283efc61300894274ae6b5a7a983d7caf3019fcef0e"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to offer higher dose versions of weight-loss drugs on website",
    "summary": "U.S. drugmaker Eli Lilly said on Monday it will offer the higher dose versions of its popular weight-loss drug Zepbound on its website LillyDirect. The company said 12.5 milligrams and...",
    "url": "https://finnhub.io/api/news?id=bb1506562e3ba217b55eeeccf56aa2746048a7b8d2535397160e540bb50bdcc1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750057511,
      "headline": "Lilly to offer higher dose versions of weight-loss drugs on website",
      "id": 135299580,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "U.S. drugmaker Eli Lilly said on Monday it will offer the higher dose versions of its popular weight-loss drug Zepbound on its website LillyDirect. The company said 12.5 milligrams and...",
      "url": "https://finnhub.io/api/news?id=bb1506562e3ba217b55eeeccf56aa2746048a7b8d2535397160e540bb50bdcc1"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to Offer All Approved Zepbound Doses via LillyDirect Self-Pay Pharmacy",
    "summary": "Eli Lilly and Co: * LILLY TO OFFER ALL APPROVED DOSES OF ZEPBOUNDSINGLE-DOSE VIALS THROUGH LILLYDIRECT SELF PAY PHARMACYSOLUTIONS * ELI LILLY AND CO - ALL APPROVED...",
    "url": "https://finnhub.io/api/news?id=5fd5518930d0078513ac0e83b3293fc1ae65c70f3868990ffa3aa8294ad3199c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750056548,
      "headline": "Lilly to Offer All Approved Zepbound Doses via LillyDirect Self-Pay Pharmacy",
      "id": 135299439,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Co: * LILLY TO OFFER ALL APPROVED DOSES OF ZEPBOUNDSINGLE-DOSE VIALS THROUGH LILLYDIRECT SELF PAY PHARMACYSOLUTIONS * ELI LILLY AND CO - ALL APPROVED...",
      "url": "https://finnhub.io/api/news?id=5fd5518930d0078513ac0e83b3293fc1ae65c70f3868990ffa3aa8294ad3199c"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: The Strength To Withstand Challenges",
    "summary": "Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See why NVO stock is a buy.",
    "url": "https://finnhub.io/api/news?id=8fc0cb17f5b7034224c44e4b69f68773293485f2b393b08f27ed8272093b3a88",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750048155,
      "headline": "Novo Nordisk: The Strength To Withstand Challenges",
      "id": 135296271,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2112991930/image_2112991930.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See why NVO stock is a buy.",
      "url": "https://finnhub.io/api/news?id=8fc0cb17f5b7034224c44e4b69f68773293485f2b393b08f27ed8272093b3a88"
    }
  }
]